As you might know, Travere Therapeutics, Inc. ( NASDAQ:TVTX ) just kicked off its latest quarterly results with ...

Q1 2025 Management View CEO Eric Dube reported strong progress for the quarter, highlighting FILSPARI's foundational role in treating IgA nephropathy (IgAN). Net sales of FILSPARI increased 13% ...

Good afternoon, and welcome to the Travere Therapeutics First Quarter and Full Year 2025 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Shares of Travere Therapeutics were trading at $20.08 as of April 29. Over the last 52-week period, shares are up 236.04%.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $1.76 per share a year ago.

SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Thursday reported a loss of $41.2 million in its first quarter. The San Diego-based company said it had a loss of 47 ...

TVTX opened at $18.33 on Monday. Travere Therapeutics, Inc. has a twelve month low of $5.24 and a twelve month high of $25.29. The firm has a market cap of $1.63 billion, a price-to-earnings ratio ...

The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 55 cents per share. The drug developer posted revenue of $81.7 ...